Patheon, the pharmaceutical services business owned by DPx Holdings B.V., will showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI/ICSE Worldwide from Tuesday, Oct. 7, to Thursday, Oct. 9, in Paris Nord Villepinte, France. CPhI/ICSE Worldwide 2014 will host 35,000 attendees and 2,500 exhibitors from 140 countries, making it the world’s leading pharmaceutical networking event.
At CPhI/ICSE Worldwide, Patheon will introduce its new end-to-end development offering, OneSource™, which now provides a single, seamless solution to customers for Phase I through Phase II projects, delivering a simplified process for both drug substance and drug product development. With the launch of OneSource, Patheon will connect its services from drug substance to drug products, focusing on simplicity, speed and uncompromised quality. The deep expertise in development services and large scale production will enable Patheon to seamlessly integrate all utilized technologies in one, lean process, which will deliver additional customer value. The OneSource offering is led by Lukas Utiger, Ph.D., who will give a presentation at the Speaker’s Corner at CPhI/ICSE Worldwide on Wednesday, Oct. 8 at 2:00 pm., to further educate attendees on the full set of offerings available from Patheon.
“After much work, we are pleased to provide customers OneSource, which is available for Phase I through Phase II projects,” said Lukas Utiger, Ph.D., president, DPx Fine Chemicals (formerly DSM Fine Chemicals) and Integrated Offering. “We continue to streamline this offering and have future plans to provide similar simplicity to Phase III through commercial scale capabilities as well. We feel strongly that it is important to bring fast and simple solutions to our customers that really address their needs.”
Additionally, representatives from Banner Life Sciences ™, another business unit of DPx Holdings, will feature research and development capabilities, proprietary pharmaceutical technologies and marketing of prescription and over-the-counter and nutritional proprietary products.
Patheon, DPx Fine Chemicals™ and Banner Life Sciences executives, technical and scientific experts attending CPhI/ICSE Worldwide will be available to discuss the company’s full services and capabilities. Representatives can be found at booth 1H9 for the duration of the conference.
About DPx Holdings
DPx Holdings B.V. (patheon.com/DPx) is the privately held parent company of the Patheon, DPx Fine Chemicals and Banner Life Sciences businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. DPx Holdings B.V. was founded in 2014 as a result of the merger of Patheon and DSM Pharmaceutical Products and is owned 51% by JLL Partners and 49% by Royal DSM. With a global headquarters in Durham, N.C., DPx Holdings B.V. has a footprint of more than 20 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPx Holdings B.V. offers customers unsurpassed quality, end-to-end services and value through its three business units.
Patheon® (patheon.com) is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms, including large and small molecule API. Patheon, a business unit of DPx Holdings B.V., encompasses the combined commercial manufacturing capabilities and pharmaceutical product development services, as well as offers a full array of biologic services and pharmaceutical active pharmaceutical ingredients (API) development. Patheon is #1 in product development services, #2 in commercial scale product manufacturing and is #1 in quality.
About DPx Fine Chemicals™
DPx Fine Chemicals™ (dpxfinechemicals.com), formerly DSM Fine Chemicals, is a business unit of DPx Holdings B.V., and is a leading provider of high-quality fine chemicals including agricultural and crop protection products, intermediates and maleic anhydride tree chemicals. The primary focus of DPx Fine Chemicals is partnering with companies in the custom synthesis of their unique compounds; it also offers a portfolio of fine chemical products important for multiple industries.
About Banner Life Sciences™
Established in 2013, Banner Life Sciences™ (bannerls.com) was formed as a result of the acquisition of Banner Pharmacaps by Patheon®. Banner Life Sciences is now a business unit of DPx Holdings B.V. and is dedicated to the research and development, in-licensing, out-licensing and commercialization of innovative formulation technologies, as well as the marketing of prescription, over-the-counter and nutritional proprietary products.